TY - JOUR
T1 - Enhancing Effect of Medium-Chain Triglycerides on Intestinal Absorption of d-α-Tocopherol Acetate from Lecithin-Dispersed Preparations in the Rat
AU - Fukui, Eiji
AU - Kurohara, Harumi
AU - Kageyu, Akira
AU - Kurosaki, Yuji
AU - Nakayama, Taiji
AU - Kimura, Toshikiro
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - The effect of formulations of lecithin-dispersed preparation on the absorption of d-α-tocopher-ol acetate (VEA) from the small intestine was investigated in rats. When lecithin-dispersed preparations containing VEA or polysorbate 80 (PS-80)-solubilized solution of VEA were intraduodenally administered, VEA was hydrolyzed to d-α-tocopherol (VE) and was not detected in the plasma nor in the thoracic lymph. The maximum plasma concentration (Cmax) of VE after the intraduodenal administration of a preparation consisting of VEA, soybean phosphatidylcholine (PC) and medium-chain triglycerides (MCTG) (VEA/PC/MCTG, 5/16/1 by weight) was highest among the VEA preparations, and PS-80-solubilized solution gave the lowest Cmax. AUC of VE up to 24 h was also increased by the addition of MCTG to VEA/PC preparation. In the thoracic duct-fistula rat, the transport of VE into the thoracic lymph was increased by the administration of the VEA/PC/MCTG preparation significantly more than the VEA/PC preparation; the cumulative amounts of VE recovered in the thoracic lymph up to 24 h were 23.2±0.5% and 10.9±1.5% of dose, respectively. The plasma concentration of VE was not increased in the thoracic duct-fistula rat even after the intraduodenal administration of VEA preparations, suggesting that VE is not transported directly to the systemic circulation, but by way of the lymphatic route. The lymphatic transport of VE following the intraduodenal administration of VEA/PC/MCTG preparation was markedly diminished by the simultaneous administration of Pluronic L-81 emulsion, an inhibitor of chylomicron formation. It is suggested that the chylomicron is essential to the lymphatic transport of VE from VEA preparations.
AB - The effect of formulations of lecithin-dispersed preparation on the absorption of d-α-tocopher-ol acetate (VEA) from the small intestine was investigated in rats. When lecithin-dispersed preparations containing VEA or polysorbate 80 (PS-80)-solubilized solution of VEA were intraduodenally administered, VEA was hydrolyzed to d-α-tocopherol (VE) and was not detected in the plasma nor in the thoracic lymph. The maximum plasma concentration (Cmax) of VE after the intraduodenal administration of a preparation consisting of VEA, soybean phosphatidylcholine (PC) and medium-chain triglycerides (MCTG) (VEA/PC/MCTG, 5/16/1 by weight) was highest among the VEA preparations, and PS-80-solubilized solution gave the lowest Cmax. AUC of VE up to 24 h was also increased by the addition of MCTG to VEA/PC preparation. In the thoracic duct-fistula rat, the transport of VE into the thoracic lymph was increased by the administration of the VEA/PC/MCTG preparation significantly more than the VEA/PC preparation; the cumulative amounts of VE recovered in the thoracic lymph up to 24 h were 23.2±0.5% and 10.9±1.5% of dose, respectively. The plasma concentration of VE was not increased in the thoracic duct-fistula rat even after the intraduodenal administration of VEA preparations, suggesting that VE is not transported directly to the systemic circulation, but by way of the lymphatic route. The lymphatic transport of VE following the intraduodenal administration of VEA/PC/MCTG preparation was markedly diminished by the simultaneous administration of Pluronic L-81 emulsion, an inhibitor of chylomicron formation. It is suggested that the chylomicron is essential to the lymphatic transport of VE from VEA preparations.
KW - d-α-tocopherol
KW - d-α-tocopherol acetate
KW - intestinal absorption
KW - lecithin-dispersed preparation
KW - lymphatic transport
KW - medium-chain triglyceride
KW - rat
UR - http://www.scopus.com/inward/record.url?scp=0024599246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024599246&partnerID=8YFLogxK
U2 - 10.1248/bpb1978.12.80
DO - 10.1248/bpb1978.12.80
M3 - Article
C2 - 2746453
AN - SCOPUS:0024599246
SN - 0918-6158
VL - 12
SP - 80
EP - 86
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 2
ER -